Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Oct. 31, 2014, 54 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $105.45 to $209,435,400.00.

Highlighted Stocks Traded by Insiders:

Cognizant Technology Solutions (CTSH) - FREE Research Report

Coburn Gordon, who is President at Cognizant Technology Solutions, sold 45,000 shares at $47.00 on Oct. 31, 2014. Following this transaction, the President owned 88,162 shares meaning that the stake was reduced by 33.79% with the 45,000-share transaction.

The shares most recently traded at $49.24, up $2.24, or 4.55% since the insider transaction. Historical insider transactions for Cognizant Technology Solutions go as follows:

  • 4-Week # shares sold: 7,990
  • 12-Week # shares sold: 7,990
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 46,607

The average volume for Cognizant Technology Solutions has been 5.8 million shares per day over the past 30 days. Cognizant Technology Solutions has a market cap of $29.2 billion and is part of the technology sector and computer software & services industry. Shares are down 4.97% year-to-date as of the close of trading on Friday.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates in four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. The company has a P/E ratio of 21.4. Currently, there are 11 analysts who rate Cognizant Technology Solutions a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTSH - FREE

TheStreet Quant Ratings rates Cognizant Technology Solutions as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Cognizant Technology Solutions Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Omnicom Group (OMC) - FREE Research Report

Crawford Bruce, who is Chairman at Omnicom Group, sold 21,600 shares at $70.28 on Oct. 31, 2014. Following this transaction, the Chairman owned 155,150 shares meaning that the stake was reduced by 12.22% with the 21,600-share transaction.

The shares most recently traded at $72.43, up $2.15, or 2.97% since the insider transaction. Historical insider transactions for Omnicom Group go as follows:

  • 4-Week # shares sold: 1,932
  • 12-Week # shares sold: 1,932
  • 24-Week # shares sold: 1,932

The average volume for Omnicom Group has been 1.4 million shares per day over the past 30 days. Omnicom Group has a market cap of $17.6 billion and is part of the services sector and media industry. Shares are down 3.38% year-to-date as of the close of trading on Friday.

Omnicom Group Inc., together with its subsidiaries, operates as an advertising, marketing, and corporate communications services company in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The stock currently has a dividend yield of 2.83%. The company has a P/E ratio of 17.3. Currently, there are 6 analysts who rate Omnicom Group a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMC - FREE

TheStreet Quant Ratings rates Omnicom Group as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, notable return on equity, reasonable valuation levels and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Omnicom Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 175,000 shares at $66.58 on Oct. 31, 2014. Following this transaction, the 10% Owner owned 132.3 million shares meaning that the stake was reduced by 0.13% with the 175,000-share transaction.

The shares most recently traded at $66.33, down $0.25, or 0.38% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 212,750
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 832,750
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 2.5 million

The average volume for Eli Lilly and has been 3.9 million shares per day over the past 30 days. Eli Lilly and has a market cap of $74.4 billion and is part of the health care sector and drugs industry. Shares are up 30.06% year-to-date as of the close of trading on Friday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 2.93%. The company has a P/E ratio of 26.7. Currently, there are 6 analysts who rate Eli Lilly and a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null